Canada Pfizer Vaccine Contract

As the government prepares for the future, the country is still grappling with a turbulent third wave, with the only cure being more vaccines in more weapons. Financial details of the deal were not disclosed, but terms were based on the time of delivery and the volume of the cans. As requested by the Canadian government, deliveries of the vaccine candidate are scheduled for the course of 2021. On July 27, 2021, the Canadian government announced that Canada had reached an important milestone with the receipt of more than 66 million doses of COVID-19 vaccines. This meant that Canada had received enough doses to fully vaccinate all eligible persons in Canada. “This agreement is part of our commitment to fight the pandemic by supporting the global supply of our vaccine candidate. Our teams are working diligently to ensure that the lead product candidate undergoes clinical development in order to request a regulatory review as early as October. At the same time, Pfizer and BioNTech continue to expand their production capacity to produce up to 100 million doses in 2020 and more than one billion doses in 2021. Since we launched the Lightspeed project, our goal has always been clear: to make a potential vaccine available to the public as quickly as possible – worldwide.

This agreement is another step in that direction,” said Sean Marett, Chief Commercial Officer and Chief Commercial Officer at BioNTech. Canada has ordered 286.9 million syringes of various sizes to meet a number of vaccine delivery requirements. These include 196.7 million 1-milliliter syringes, including 180.8 million low-dead-volume syringes and 14.5 million ultra-low-dead volume syringes. Canada also ordered 81 million low-dead volume needles. We expect to have a sufficient supply of syringes to administer pediatric doses. So far, Pfizer`s ongoing study suggests that the company`s two-dose vaccine will remain highly effective for at least six months and probably longer. People who received the Moderna vaccine still had remarkable amounts of anti-virus antibodies, even six months after the second injection required. PSPC has contracts on behalf of PHAC for the purchase of: KIRKLAND, QC, 23. April 2021 – Pfizer Canada announced today that it has entered into an agreement with the Government of Canada to provide up to 125 million doses of Pfizer-BioNTech`s COVID-19 vaccine in 2022 and 2023, with options to administer up to 60 million additional doses in 2024. The Prime Minister says that 30% of eligible adults in Canada have received at least one vaccine. All eligible Canadians should receive at least one dose by the end of June. But less than a month after the contract was signed, Health Canada`s senior medical advisor, Dr.

Supriya Sharma, reported that her department was about two weeks away from giving the green light to the vaccine. In addition to their commitments with governments, Pfizer and BioNTech have expressed interest in potential delivery to the COVAX facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO) to provide governments, including those in emerging markets, with Rapid access to a broad portfolio of COVID-19 vaccine candidates using a range of technology platforms. produced by several manufacturers around the world. This appears to have sent Canada back to Pfizer to see if its contract could be changed to get doses delivered earlier. On December 4, Canada and Pfizer signed a change that allows it, but at a price. Pfizer`s contract was one of eight that were quietly shared with the health committee on Friday. The committee is investigating Canada`s response to COVID-19 and, as a result, has requested numerous documents from the government. This is the first time Canada has provided details about its contracts, but there are a lot of blank pages and deleted details, including any information related to prices or delivery schedules. In most cases, initial agreements were signed through memoranda of understanding and condition sheets with international sources to ensure Canada`s early access to an early supply of vaccines, while allowing time for the regulatory process and the development of complex conditions with manufacturers. Vaccines are so new that experts do not yet have reliable data on how long they are protected or whether they will be affected by emerging variants of the virus. Opposition parties asked the government to publish the contracts as part of a request for a full document related to the COVID-19 pandemic in October. At the time, government ministers said the release of the documents could jeopardize Canada`s ability to obtain vaccines.

Since then, redacted documents have been provided semi-regularly to the Health Committee, often late on a Friday. Canada is committed to providing a comprehensive and global response to the pandemic and is working to ensure that countries around the world have access to COVID-19 vaccines through its investments in the Covid-19 Global Vaccine Access Facility (COVAX) and the donation of surplus vaccine doses. OTTAWA – As part of its recent procurement efforts, the federal government has reached an agreement with Pfizer to procure 35 million COVID-19 booster vaccines for next year and $30 million for the following year. The contracts include previously unknown details, including Pfizer`s early dose premium and the fact that Canada is allowed to donate doses from five of the suppliers to other countries or international aid organizations such as the World Health Organization or the COVAX Vaccine Alliance. The details are contained in heavily redacted contracts that were forwarded to the House of Commons Health Committee on Friday night, but any details about the price paid or how the delivery schedule was changed were removed before the contract was released. Vaccines usually require years of research and testing before they enter people`s arms. .